Investigating a new treatment target for a rare blood disease
JAK1/2 as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target
This study is looking at idiopathic multicentric Castleman disease (iMCD) to better understand how it affects the body and to find new treatment options for patients who aren't getting better with current therapies, so if you have iMCD, you might have the chance to help test some new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11094716 on NIH RePORTER |
What this research studies
This research focuses on idiopathic multicentric Castleman disease (iMCD), a serious condition that causes abnormal growth of lymphatic tissue and can lead to multiple organ dysfunction. The study aims to understand the underlying mechanisms of iMCD, particularly the role of certain signaling pathways that may contribute to the disease's progression. By examining the behavior of immune cells in patients, the researchers hope to identify new therapeutic targets that could improve treatment options for those who do not respond to current therapies. Patients may be involved in trials that explore the effects of new treatments aimed at regulating these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic multicentric Castleman disease who have not responded to existing treatments.
Not a fit: Patients with other forms of Castleman disease or those who have not been diagnosed with iMCD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with iMCD, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting mTOR signaling in iMCD, indicating that this approach may lead to meaningful advancements in treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Fajgenbaum, David C — University of Pennsylvania
- Study coordinator: Fajgenbaum, David C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.